The Senate Rules Committee advanced House Concurrent Resolution 3, which honors Dr. Brian Druker for his research and leadership in cancer treatment and early detection, following multiple witnesses who described his scientific and fundraising achievements.

Representative Hai Pham opened testimony by describing Dr. Drucker’s role in developing Gleevec and the institutional impact of his work: "he created this medication called Gleevec which essentially put OHSU on the map," and he credited Drucker’s leadership in helping secure the Knight Cancer Institute’s major fundraising campaign.

Jeff Baker, a volunteer advisor to the Knight Cancer Institute, said Dr. Drucker "believed 95 percent of the patients treated at OHSU for cancer could be cured" if cancers are detected early, and described fundraising and the creation of the Knight Cancer Research Building. Steve Janik, former OHSU Foundation trustee, added that Dr. Drucker pioneered molecular approaches to cancer and helped develop blood tests that can detect dozens of cancers.

Committee action: Senator Manning moved the resolution to the floor with a "be adopted" recommendation; the motion passed on roll call.

Why it matters: supporters framed HCR 3 as recognition of scientific leadership that produced treatments (Gleevec), advanced precision medicine, and led statewide fundraising that created research capacity at OHSU. Witnesses emphasized both patient care and the broader research infrastructure Dr. Drucker helped to establish.

Next steps: HCR 3 will be carried to the Senate floor for consideration.

Evidence: public testimony recorded in the Rules Committee hearing on May 21, 2025.